Tenomix has developed a benchtop, printer-sized robotics system that uses ultrasound and artificial intelligence to automate the manual lymph node screening process used in colorectal cancer staging. The system is intended to reduce missed cancerous lymph nodes that can lead to improper staging and treatment. The device is currently undergoing validation in hospitals across the U.S. and Canada. Tenomix envisions the technology as a versatile platform with scalable software to support the pathology workflow. The company closed a $2 million all‑Canadian seed round to advance development and commercialization. Leadership says the funding and local ecosystem support will help the company build a profitable business and give pathology staff better tools to improve patient care.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2024